Data / Form D filings / Kura Oncology, Inc.
Kura Oncology, Inc.: Form D filings
Kura Oncology, Inc., a biotechnology company in San Diego, CA, filed 2 Form D notices with the SEC between 2015 and 2024. The latest, on February 5, 2024, reports $150 million sold of a $150 million offering to 10 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 12730 HIGH BLUFF DRIVE, SUITE 400, San Diego, CA, 92130
- Phone
- (858) 500-8800
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1422143
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 5, 2024 | New notice | $150,000,808 | $150,000,808 | 10 | Jan 26, 2024 | sec.gov | |
| Mar 19, 2015 | New notice | $91,691,679 | $91,691,679 | 356 | Mar 6, 2015 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| DIANE PARKS | Director | |
| TERESA BAIR | Executive Officer | |
| FAHEEM HASNAIN | Director | |
| HELEN COLLINS | Director | |
| BRIAN POWL | Executive Officer | |
| THOMAS MALLEY | Director | |
| MARY SZELA | Director | |
| KATHLEEN FORD | Executive Officer | |
| CAROL SCHAFER | Director | |
| TROY WILSON | Executive Officer, Director | |
| STEPHEN DALE | Executive Officer |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Feb 5, 2024 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Kura Oncology, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.